drugset / Trial / NCT07188025
ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer
Phase 3
Recruiting
103 enrolled
Erasmus Medical Center
BOOG Study Center · collabDutch Colorectal Cancer Group (DCCG) · collabProspectief Landelijk CRC Cohort (PLCRC) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to investigate whether adjuvant chemotherapy can prevent disease recurrence in patients with high-risk rectal cancer who have detectable ctDNA after surgery. The main research question the REACT study aims to answer is: \- Does adjuvant chemotherapy improve disease-free survival in patients with high-risk rectal cancer with detectable ctDNA after surgery? Interventions: \- Patients with detectable ctDNA after surgery and randomised to the experimental group will be offered adjuvant chemotherapy (4 cycles CAPOX/6 cycles FOLFOX) within 12 weeks after surgery.
Timeline
- Start
- 2025-10-14
- Primary completion
- 2030-10
- Completion
- 2035-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | — | — |
| Subject | Leucovorin | Small molecule | — | — |
| Subject | Oxaliplatin | Small molecule | — | — |
| Subject | fluorouracil | Small molecule | — | — |